INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 439m ago
HOUSE PTR38m ago
SEC 13F38m ago
ROBINHOOD CHAIN38m ago
SEC FORM 4/Tax withholdingVerified data

Gassert Chad reported ANIP

SVP - CORP. DEV. & STRATEGY · ANI PHARMACEUTICALS INC · Common Stock

Side
F
Value
$326K
Shares
4,269
Price
$76.25
Executed
Feb 11, 2026
Disclosed
Feb 13, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 11 executedFeb 13, 2026 disclosed

ANIP · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
15/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+11 / 25

$326K reported value · 6.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ANIP

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CP
    Carey Stephen P.SVP & CFO
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$208K
    2,850 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    17
    LN
    Lalwani NikhilDirector, PRESIDENT & CEO
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$388K
    5,400 sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    8
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$37K
    500 sh
    		Oct 13, 2026Oct 13, 2026
    traded Oct 13, 2026
    		+0dSEC FORM 4

    Evidence

    14
    CP
    Carey Stephen P.SVP & CFO
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$208K
    2,850 sh
    		Sep 29, 2026Sep 30, 2026
    traded Sep 29, 2026
    		+1dSEC FORM 4

    Evidence

    22
    LN
    Lalwani NikhilDirector, PRESIDENT & CEO
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$383K
    5,400 sh
    		Sep 15, 2026Sep 16, 2026
    traded Sep 15, 2026
    		+1dSEC FORM 4

    Evidence

    8
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$35K
    500 sh
    		Sep 14, 2026Sep 14, 2026
    traded Sep 14, 2026
    		+0dSEC FORM 4

    Evidence

    18
    TJ
    Thoma JeanneDirector
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$72K
    1,000 sh
    		Sep 11, 2026Sep 14, 2026
    traded Sep 11, 2026
    		+3dSEC FORM 4

    Evidence

    19
    GO
    Gosebruch Henry ODirector
    ANIPANI PHARMACEUTICALS INC
    Grant or award
    		A—
    6,662 sh
    		Aug 19, 2026Aug 27, 2026
    traded Aug 19, 2026
    		+8dSEC FORM 4

    Evidence

    16
    LN
    Lalwani NikhilDirector, PRESIDENT & CEO
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$401K
    5,400 sh
    		Aug 25, 2026Aug 26, 2026
    traded Aug 25, 2026
    		+1dSEC FORM 4

    Evidence

    8
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$38K
    500 sh
    		Aug 13, 2026Aug 13, 2026
    traded Aug 13, 2026
    		+0dSEC FORM 4

    Evidence

    29
    GO
    Gutwerg OriSVP, GENERICS
    ANIPANI PHARMACEUTICALS INC
    Open-market sale
    		SELL$243K
    3,162 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    8
    CP
    Carey Stephen P.SVP & CFO
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$240K
    2,850 sh
    		Jun 29, 2026Jun 30, 2026
    traded Jun 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$41K
    500 sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    31
    LJ
    Leonard Matthew JDirector
    ANIPANI PHARMACEUTICALS INC
    Grant or award
    		A—
    4,357 sh
    		May 21, 2026Jun 10, 2026
    traded May 21, 2026
    		+20dSEC FORM 4

    Evidence

    23
    TJ
    Thoma JeanneDirector
    ANIPANI PHARMACEUTICALS INC
    Grant or award
    		A—
    4,357 sh
    		May 21, 2026Jun 10, 2026
    traded May 21, 2026
    		+20dSEC FORM 4

    Evidence

    1
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$39K
    500 sh
    		May 13, 2026May 13, 2026
    traded May 13, 2026
    		+0dSEC FORM 4

    Evidence

    1
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$39K
    500 sh
    		Apr 13, 2026Apr 13, 2026
    traded Apr 13, 2026
    		+0dSEC FORM 4

    Evidence

    6
    CM
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$36K
    500 sh
    		Mar 13, 2026Mar 13, 2026
    traded Mar 13, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DK
    Davis KristaSVP, CHIEF HR OFFICER
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$111K
    1,485 sh
    		Mar 6, 2026Mar 10, 2026
    traded Mar 6, 2026
    		+4dSEC FORM 4

    Evidence

    16
    DK
    Davis KristaSVP, CHIEF HR OFFICER
    ANIPANI PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$377K
    5,087 sh
    		Mar 9, 2026Mar 10, 2026
    traded Mar 9, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001871002-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 11, 2026
    Published
    Feb 13, 2026
    Ingested by INSIDER
    Nov 5, 04:17 UTC
    Last re-read
    Nov 5, 04:17 UTC

    Extracted facts

    Filer
    Gassert Chad
    Role
    SVP - CORP. DEV. & STRATEGY
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    ANI PHARMACEUTICALS INC
    Ticker
    ANIP
    Shares
    4,269
    Price per share
    $76.25
    Value
    $325,511
    Execution date (reported)
    Feb 11, 2026
    Owned after transaction
    69.3K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 4,269
    • Price: $76.25

    = $325,511

    What this establishes

    Gassert Chad filed this Form 4 reporting a tax withholding of ANIP on Feb 11, 2026. It became public on Feb 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP - CORP. DEV. & STRATEGY
    Gassert Chadcik:0001871002
    Issuer
    ANI PHARMACEUTICALS INCcik:0001023024

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.